Outcomes of Continuous Infusion Versus Intermittent Bolus Injection of Furosemide in Patients with Acute Decompensated Heart Failure (ADHF): A Prospective Observational Comparative Study
2026· International journal of research and innovation in social science· Vol 10, pp. 4192-4205· 0 citations
TL;DR
Both dosing methods were effective in relieving symptoms of acute decompensated heart failure: Continuous infusion produced greater diuresis, while bolus dosing also remained effective.
Abstract
Acute decompensated heart failure is a frequent cause of hospital admission and is commonly managed with intravenous loop diuretics. Furosemide is usually given either as intermittent bolus doses or as a continuous infusion, but the optimal method of administration remains uncertain in routine clinical practice. The study included forty patients (n=40, 20 per group) diagnosed with heart failure, encompassing both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Patients presenting with symptoms like dyspnea or edema were excluded if their systolic blood pressure fell below 90 mm Hg or if their condition was critically ill. A total of 40 patients with acute decompensated heart failure were included in the study, with 20 patients in each treatment group. Baseline clinical and laboratory parameters were comparable between the groups. Urine output during the three-day treatment period was higher in patients treated with continuous furosemide infusion than in those who received bolus doses (p = 0.037). Serum creatinine, sodium, and potassium levels showed no significant differences between the two groups. Vital signs remained stable in both treatment arms throughout the study period. Both dosing methods were effective in relieving symptoms of acute decompensated heart failure. Continuous infusion produced greater diuresis, while bolus dosing also remained effective. The choice of treatment should be based on the patient’s clinical condition. Further studies with larger samples are required to assess long-term outcomes.
BACKGROUND
The combination of hypertonic saline solution (HSS) and high-dose furosemide may enhance diuretic response in acute heart failure (AHF), but evidence in real-world populations, particularly very elderly patients admitted to internal medicine wards, remains limited.
METHODS
Retrospective, single-center, unc...
G. Ropero-Luis, M. E. Carmona-Moreno, M. Melgar-Velasco et al.· European journal of internal...· 2 citations
Outpatient management of advanced heart failure is challenging. Intravenous inotropes, administered intermittently or continuously, may serve as destination therapy or as a bridge to definitive treatment in selected patients.
This study aims to evaluate the efficacy and safety of ambulatory milrinone in ad...
A. Rioux, É. Voisine, S. Berube et al.· European Heart Journal· 0 citations
Rapid and sustained decongestion in acute heart failure with reduced ejection fraction (HFrEF) remains a therapeutic challenge, particularly in patients with diuretic resistance. Sequential nephron blockade with acetazolamide may enhance decongestion during hospitalization and, when continued intermittently after...
R. Sabido, S. Ramos, M. Lagunas et al.· European Heart Journal· 0 citations
Heart rate control may represent a key therapeutic target in cardiogenic shock (CS), particularly in patients who experience failure of catecholamine weaning. Ivabradine, a selective sinus node inhibitor, could improve ventriculo-arterial coupling and hemodynamic stability; however, clinical data in this setting...
O. Haddar, S. Charfeddine, Y. Kobbi et al.· European Heart Journal· 0 citations
Subgroup findings suggest differential benefits according to ventricular function and renal status, supporting early SGLT2 inhibitor use in acute heart failure.
N. Benameur, A. Molina, M. El Mesbahi et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.